A5030768494- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Spondyloarthritis Studies and Treatments
- Lymphoma Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Bone and Joint Diseases
- Inflammatory mediators and NSAID effects
- Osteoarthritis Treatment and Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Gout, Hyperuricemia, Uric Acid
- Pharmaceutical studies and practices
- Dermatology and Skin Diseases
- Viral Infections and Immunology Research
- Medication Adherence and Compliance
- Drug-Induced Adverse Reactions
- Statistical Methods in Clinical Trials
- Tuberculosis Research and Epidemiology
- Antiplatelet Therapy and Cardiovascular Diseases
- Peripheral Neuropathies and Disorders
- Mycobacterium research and diagnosis
New York University
2013-2024
University of Alabama at Birmingham
2009-2024
Navitas Systems (United States)
2022-2024
Gilead Sciences (United States)
2024
University of Massachusetts Chan Medical School
2010-2020
Columbia University
2020
Albany Medical Center Hospital
2015-2020
Center for Rheumatology
2015-2020
Columbia University Irving Medical Center
1995-2020
NYU Langone Health
2007-2020
Objective To examine the association of cardiovascular events with tumour necrosis factor (TNF) α antagonist use compared non-biological disease-modifying antirheumatic drug (DMARD) utilisation in patients rheumatoid arthritis (RA). Methods The study population included 10 156 enrolled Consortium Rheumatology Researchers North America RA registry. Three cohorts were defined based on three mutually exclusive categories, including TNF antagonists, methotrexate and other DMARDs. HR calculated...
<h3>Objective</h3> To determine the relationship of disease activity to infections in patients with rheumatoid arthritis (RA). <h3>Methods</h3> From CORRONA database, incidence physician-reported RA on stable disease-modifying antirheumatic drug, biological, and corticosteroid therapy for at least 6 months was ascertained. Two composite measures were defined: clinical index (CDAI) score 28 (DAS28). Incident rate ratios (IRR) calculated using generalised estimating equation Poisson regression...
Use of several immunomodulatory agents has been associated with reduced numbers cardiovascular (CV) events in epidemiologic studies rheumatoid arthritis (RA). However, it is unknown whether time-averaged disease activity RA correlates CV events.We studied patients whose cases were followed a longitudinal US-based registry. Time-averaged was assessed during followup using the area under curve Clinical Disease Activity Index (CDAI), validated measure activity. Age, sex, presence diabetes...
Background Cardiovascular (CV) disease has a major impact on patients with rheumatoid arthritis (RA), however, the relative contributions of traditional CV risk factors and markers RA severity are unclear. The authors examined importance in predicting events. Methods A prospective longitudinal cohort study was conducted setting CORRONA registry USA. Baseline data from subjects enrolled were to determine predictors outcomes, including myocardial infarction, stroke or transient ischemic...
Objective: To examine the association of methotrexate (MTX) and tumour necrosis factor (TNF) antagonists with risk infectious outcomes including opportunistic infections in patients rheumatoid arthritis (RA). Methods: Patients RA enrolled Consortium Rheumatology Researchers North America (CORRONA) registry prescribed MTX, TNF or other disease-modifying antirheumatic drugs (DMARDs) were included. The primary incident overall infections. Incident rate ratios calculated using generalised...
Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic (PsA) and ulcerative colitis, has been investigated in psoriasis (PsO). Routine pharmacovigilance an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467 ) patients aged ≥50 years with ≥1 cardiovascular risk factor identified higher frequency pulmonary embolism (PE) all-cause mortality receiving 10 mg twice daily versus those tumour necrosis...
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those new biological disease‐modifying antirheumatic drugs (bDMARDs) within United States (US) Corrona RA registry. Methods IRs (number first events/100 patient‐years) major cardiovascular events (MACE), serious infection (SIEs), herpes zoster (HZ), malignancies, death were estimated...
Introduction: Potential hepatotoxicity associated with disease-modifying antirheumatic drugs (DMARDs) requires laboratory monitoring. In patients rheumatoid arthritis (RA) or psoriatic (PsA), the incidence of elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes methotrexate (MTX), leflunomide (LEF) and MTX+LEF versus other DMARDs was examined. Methods: Patients RA PsA enrolled in Consortium Rheumatology Researchers North America (CORRONA) initiating were identified....
The ability of antiinflammatory strategies to alter cardiovascular risk has not been rigorously examined. Colchicine is an agent that affects macrophages, neutrophils, and endothelial cells, all which are implicated in the pathogenesis disease. We examined whether colchicine use was associated with a reduced myocardial infarction (MI) patients gout.We conducted retrospective, cross-sectional study International Classification Diseases, 9th ed, code for gout electronic medical record (EMR)...
To evaluate whether gene expression profiles could serve as biomarkers of symptomatic knee osteoarthritis (OA) by examining in peripheral blood leukocytes (PBLs) from patients with OA compared those non-OA controls, and to determine candidate genomic (PBL inflammatory genes) predict an increased risk disease progression radiographic OA.Three independent cohorts control subjects were studied. Two (a learning cohort a validation cohort) recruited at New York University Hospital for Joint...
<h3>Purpose</h3> To compare the effectiveness of anti-tumour necrosis factor (TNF) agents in biologically naive and 'switched' rheumatoid arthritis (RA) patients. <h3>Methods</h3> RA patients enrolled CORRONA registry newly prescribed adalimumab (n=874), etanercept (n=640), or infliximab (n=728) were stratified based on previous anti-TNF use. Clinical at 6, 12 24 months was examined using modified American College Rheumatology response criteria (mACR20/50/70) achievement remission (28-joint...
Objective Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), but CV risk prediction scores derived from general population do not accurately predict RA patients. The goal these analyses was to develop and internally validate an expanded score for RA. Methods Study participants were patients with no known CVD Consortium Rheumatology Researchers North America registry. Two‐thirds cohort used derive score, one‐third internal validation. Traditional...
To evaluate the relationships between both quantitative and semiquantitative assessments of degree knee synovitis on 3T magnetic resonance imaging (MRI) severity osteoarthritis (OA) radiography.Fifty-eight patients with OA underwent nonfluoroscopic fixed-flexion radiography. In addition, dynamic contrast-enhanced MRI knees was performed, before after gadolinium administration, to quantify synovial membrane volume (SV) as a measure proliferation (expressed SV), measures were also applied...
Clinical trials of new treatments for rheumatoid arthritis (RA) typically require subjects to have an elevated acute phase reactant (APR), in addition tender and swollen joints. However, despite the elevation individual components Disease Activity Index (CDAI) (tender joint counts patient physician global assessment), some patients with active RA may normal erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) levels thus fail meet entry criteria clinical trials. We assessed...
Objective. We analyzed the characteristics of patients with psoriatic arthritis (PsA) and without axial involvement in US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Methods. All were included who had PsA data on involvement, defined as physician-reported presence spinal at enrollment, and/or radiograph or magnetic resonance imaging showing sacroiliitis. Demographics, clinical measures, patient-reported outcomes, treatment assessed enrollment. Results. Of 1530 PsA, 192...
To characterize psoriatic arthritis (PsA) patients with dactylitis or enthesitis and evaluate the associations of these manifestations disease activity patient-reported outcomes.Using Corrona PsA/Spondyloarthritis Registry, patient characteristics, activity, outcomes at registry enrollment were assessed for PsA ages ≥18 years without enthesitis. Regression models used to outcomes, including minimal Health Assessment Questionnaire scores, pain fatigue, work productivity (Work Productivity...
<h3>Objective</h3> Liver function test (LFT) elevations are reported with the use of tumour necrosis factor inhibitors (TNF-Is). The aim this study was to compare LFT in patients rheumatoid arthritis receiving adalimumab (ADA), etanercept (ETN) or infliximab (INF) enrolled Consortium Rheumatology Researchers North America from October 2001 March 2007. <h3>Methods</h3> Alanine aminotransferase (ALT) and/or aspartate (AST) levels >1× upper limit normal (ULN) were considered and ALT/AST...
BackgroundPsoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent new treatments, there growing need to assess long-term safety and efficacy treatments in a real-world setting.ObjectiveThe objective Corrona Psoriasis Registry study comparative Food Drug Administration–approved biologic treatments.MethodsA cross-sectional patients enrolled registry, who initiated or switched systemic therapy at enrollment previous 12...
To identify the rheumatoid arthritis (RA) characteristics associated with increased herpes zoster (HZ) risk in Corrona registry RA patients, and to evaluate initiators of tumor necrosis factor inhibitors (TNFi) or non-TNFi biologic agents (among those who were currently on had been previously treated methotrexate [MTX]) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) other than MTX.Cox regression modeling estimated association between first HZ incidence selected...
To characterise the comparative effectiveness of combination therapy (a tumour necrosis factor inhibitor (TNFi) and a conventional synthetic disease-modifying antirheumatic drug (csDMARD) such as methotrexate) monotherapy (TNFi only) for psoriatic arthritis (PsA) from large US registry.The analysis included adult patients with PsA who were enrolled in Corrona database (ClinicalTrials.gov, NCT01402661), had initiated TNFi, biologic naïve, follow-up visit ≥90 days after initiation. The...
Linkages between registries and administrative data may provide a valuable resource for comparative effectiveness research. However, personal identifiers that uniquely identify individuals are not always available. Here we describe methods to link de-identified arthritis registry US Medicare data. The linked set was also used evaluate the generalizability of population.Rheumatoid (RA) patients participating in Consortium Rheumatology Researchers North America (CORRONA) were restricted...